Experiment ID | EXP00340 |
Reference | Title: Cross-species identification of a plasma microRNA signature for detection,therapeutic monitoring, and prognosis in osteosarcoma. Author: Allen-Rhoades W, Kurenbekova L, Satterfield L, Parikh N, Fuja D,Shuck RL, Rainusso N, Trucco M, Barkauskas DA, Jo E, Ahern C,Hilsenbeck S, Donehower LA, Yustein JT. Journal: Cancer Med. 2015 Jul;4(7):977-88. doi: 10.1002/cam4.438. Epub 2015 Mar 17. Abstract: Osteosarcoma (OS) is the primary bone tumor in children and young adults.Currently, there are no reliable, noninvasive biologic markers to detect thepresence or progression of disease, assess therapy response, or provide upfrontprognostic insights. MicroRNAs (miRNAs) are evolutionarily conserved, stable,small noncoding RNA molecules that are key posttranscriptional regulators and areideal candidates for circulating biomarker development due to their stability in plasma, ease of isolation, and the unique expressions associated with specificdisease states. Using a qPCR-based platform that analyzes more than 750 miRNAs,we analyzed control and diseased-associated plasma from a genetically engineered mouse model of OS to identify a profile of four plasma miRNAs. Subsequentanalysis of 40 human patient samples corroborated these results. We alsoidentified disease-specific endogenous reference plasma miRNAs for mouse andhuman studies. Specifically, we observed plasma miR-205-5p was decreased2.68-fold in mice with OS compared to control mice, whereas, miR-214, andmiR-335-5p were increased 2.37- and 2.69-fold, respectively. In human samples,the same profile was seen with miR-205-5p decreased 1.75-fold in patients withOS, whereas miR-574-3p, miR-214, and miR-335-5p were increased 3.16-, 8.31- and2.52-fold, respectively, compared to healthy controls. Furthermore, low plasmalevels of miR-214 in metastatic patients at time of diagnosis conveyed asignificantly better overall survival. This is the first study to identify plasmamiRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients. PMID: 25784290 |
Expressiion Profile | Description: Plasma profiling of miRNAs in human specimens from osteosarcoma patients. Organism: Homo sapiens GEO ID: GSE65071 Platform: GPL19631 Number of samples: 35 |
Design and Sample | Cancer Type: sarcoma Cancer SubType: osteosarcoma Cell Line: N/D Experimental Design: blood Case Sample: blood from sarcoma Control Sample: normal blood Num of Case: 20 Num of Control: 15 Quantification Software: limma Num of miRNAs: 355 |
Identification | Num of Up: 126 Num of Down: 143 |